Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Climb Bio Q3 2026 Results: Net Loss of $14.6M, Loss Widens

Climb Bio, Inc. is a clinical-stage biotechnology company focused on immunology and autoimmune diseases, specifically developing product candidates budoprutug and CLYM116. As of October 30, 2026, the company had 58,738,178 shares of common stock outstanding and continues to incur significant losses with no current source of product revenue.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-14.6-12.9
EPS (diluted, $ a share)$-0.18$-0.19

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: CLYM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Climb Bio, Inc.: key numbers

Share price
$9.94Close, Nov 16
Market cap
$584M
Shares outstanding
58.74MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Climb Bio, Inc.

All →
7:13 AM ET 8-K
Financial Results

Climb Bio Financial Results

Climb Bio reported Q3 2026 financial results, highlighting a cash position of $227.6 million which provides a runway into the second half of 2028. The company initiated dosing in its Phase 2 trial for CLYM116 in IgA nephropathy and reported positive Phase 1 data supporting a best-in-class every-12-week dosing profile.

Term
Q3 2026

“We are building significant momentum across our programs, CLYM116 and budoprutug. For CLYM116, two independent datasets support a best-in-class anti-APRIL profile and initial budoprutug data from our ongoing Phase 2 PrisMN study in primary membranous nephropathy demonstrated meaningful B-cell depletion and immunologic remission at 200 mg, with potential for increased activity at higher doses.”

Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer

“Looking ahead, we are poised to enter 2027 with two promising programs, multiple anticipated data readouts across both, and the potential to initiate pivotal studies.”

Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer
6:24 AM ET 8-K
Clinical Trial Data

Climb Bio Clinical Trial Data

Climb Bio announced initial Phase 2 data from its PrisMN trial evaluating budoprutug in patients with primary membranous nephropathy (pMN), showing a 70% mean reduction in PLA2R antibody levels at Week 12 in the 200 mg cohort. Initial data from the 600 mg cohort indicated deeper B-cell depletion and greater drug exposure, supporting the ongoing evaluation of higher doses. The company also reported a case study in minimal change disease (MCD) where a patient achieved a three-year steroid-free remission following treatment.

5:27 PM ET 8-K
Clinical Trial Data

Climb Bio Clinical Trial Data

Climb Bio and Mabworks announced additional Phase 1 clinical data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, demonstrating deep and durable APRIL suppression through 12 weeks. The data showed a 33-day half-life and a 70% reduction in Gd-IgA1 at 12 weeks, supporting a potential every-12-week dosing regimen. The company remains on track to report initial Phase 2 data in the first half of 2027 and plans to initiate a global Phase 3 trial in 2027.

Counterparty
Beijing Mabworks Biotech Co., Ltd.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.